MX2022005168A - Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso. - Google Patents

Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso.

Info

Publication number
MX2022005168A
MX2022005168A MX2022005168A MX2022005168A MX2022005168A MX 2022005168 A MX2022005168 A MX 2022005168A MX 2022005168 A MX2022005168 A MX 2022005168A MX 2022005168 A MX2022005168 A MX 2022005168A MX 2022005168 A MX2022005168 A MX 2022005168A
Authority
MX
Mexico
Prior art keywords
cox
topical formulations
cyclooxygenase inhibitors
ethanol
long chain
Prior art date
Application number
MX2022005168A
Other languages
English (en)
Inventor
Thomas Hnat
Original Assignee
Smartech Topical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartech Topical Inc filed Critical Smartech Topical Inc
Publication of MX2022005168A publication Critical patent/MX2022005168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación tópica del inhibidor de la ciclooxigenasa (COX) que comprende un inhibidor de la COX-1 y/o de la COX-2, uno o más ácidos grasos monoinsaturados de cadena larga, alcoholes grasos monoinsaturados de cadena larga, terpenos o combinaciones de los mismos; y una mezcla de disolventes que comprende etanol, propilenglicol, 2-(2-Etoxietoxi)etanol y, opcionalmente, dimetilsulfóxido.
MX2022005168A 2019-11-06 2020-11-05 Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso. MX2022005168A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962931466P 2019-11-06 2019-11-06
PCT/US2020/059198 WO2021092238A1 (en) 2019-11-06 2020-11-05 Topical formulations of cyclooxygenase inhibitors and their use

Publications (1)

Publication Number Publication Date
MX2022005168A true MX2022005168A (es) 2022-06-08

Family

ID=75848758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005168A MX2022005168A (es) 2019-11-06 2020-11-05 Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso.

Country Status (8)

Country Link
US (2) US20220378729A1 (es)
EP (1) EP4054549A4 (es)
JP (1) JP7515582B2 (es)
CN (1) CN114615974A (es)
AU (1) AU2020379828A1 (es)
CA (1) CA3155267A1 (es)
MX (1) MX2022005168A (es)
WO (1) WO2021092238A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117396196A (zh) * 2021-05-05 2024-01-12 智能科技专题有限公司 局部萘普生制剂及其用途
EP4112043A1 (en) * 2021-06-30 2023-01-04 GSK Consumer Healthcare SARL Nano-complex composition comprising diclofenac

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4764381A (en) 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US4983396A (en) 1985-12-06 1991-01-08 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol
JPS63225312A (ja) 1986-10-02 1988-09-20 Kao Corp 透明ないし半透明のジエリー状の化粧料
MY102980A (en) 1986-10-31 1993-03-31 Pfizer Transdermal flux enhancing compositions
US5002938A (en) 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
JP3086290B2 (ja) * 1991-07-26 2000-09-11 エスエス製薬株式会社 ジクロフェナクナトリウム貼付剤
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5614210A (en) 1995-03-31 1997-03-25 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of alfuzosin
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
EP0879597A4 (en) * 1996-02-07 2001-01-31 Tsumura & Co TRANSPARENT AQUEOUS SOLUTION OF DICLOFENAC SODIUM, MEDICINAL COMPOSITIONS, AND USES
AU718811B2 (en) 1996-10-30 2000-04-20 Theratech, Inc. Fatty acid esters of glycolic acid and its salts as permeation enhancers
KR19990047898A (ko) * 1997-12-05 1999-07-05 김윤 디크로페낙염을 유효성분으로 하는 진통소염 외용겔제
US6238683B1 (en) * 1998-12-04 2001-05-29 Johnson & Johnson Consumer Companies, Inc. Anhydrous topical skin preparations
US8980290B2 (en) * 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
PT1315502E (pt) 2000-08-30 2010-05-06 Unimed Pharmaceuticals Llc Método para tratar a disfunção eréctil e para aumentar a líbido em homens
US20050058695A1 (en) 2002-05-30 2005-03-17 Watson Pharmaccuticals, Inc. Norethindrone sustained release formulations and methods associated therewith
WO2004000242A1 (en) 2002-06-25 2003-12-31 Cosmeceutic Solutions Pty Ltd Topical cosmetic compositions
WO2004054552A1 (en) 2002-12-13 2004-07-01 Samyang Corporation Transdermal composition of an antivomiting agent
US20050020552A1 (en) 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
GR1004995B (el) 2004-05-17 2005-09-19 Παρασκευας Δαλλας Φαρμακευτικη συνθεση για τη συστηματικη χορηγηση κετοτιφαινιου μεσω του δερματος
US7618651B2 (en) 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
CN101151028A (zh) * 2005-03-03 2008-03-26 Isw集团公司 局部用凝胶组合物
JP2006265153A (ja) 2005-03-23 2006-10-05 Noevir Co Ltd ゲル組成物
US20080319092A1 (en) * 2005-08-05 2008-12-25 Nuvo Research Inc. Transdermal Drug Delivery Formulation
CA2645073A1 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
RU2463038C2 (ru) 2006-10-17 2012-10-10 Нуво Рисерч Инк. Диклофенаковый гель
PL2211837T3 (pl) 2007-06-08 2014-05-30 Troikaa Pharmaceuticals Ltd Niewodny roztwór diklofenaku do podawania miejscowego oraz sposób jego wytwarzania
EP2055298A1 (en) * 2007-10-30 2009-05-06 Novartis AG Topical composition
ATE542521T1 (de) * 2007-11-29 2012-02-15 Alltranz Inc Verfahren und zusammensetzungen zur verstärkung der lebensfähigkeit von mikronadelporen
HUP0700828A2 (en) 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
ES2562798T3 (es) 2008-08-09 2016-03-08 Merck Patent Gmbh Uso de compuestos de indol como cosmético
CA3023725C (en) 2009-10-22 2021-09-14 Vizuri Health Sciences Llc Methods of producing hydrated flavonoids and use thereof in the preparation of topical compositions
BR112012012789A2 (pt) * 2009-11-27 2016-08-16 Nuvo Res Inc formulações de ibuprofeno tópicas
JP5650239B2 (ja) 2009-12-04 2015-01-07 コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ 固体の高充填を強化するための、ポリソルベート等の高濃度の非イオン界面活性剤を含む溶解性フィルム
CA2792018A1 (en) 2010-05-10 2011-11-17 Segetis, Inc. Fragrant formulations, methods of manufacture thereof and articles comprising the same
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
ES2749323T3 (es) 2011-05-03 2020-03-19 Aponia Laboratories Inc Composiciones transdérmicas de ibuprofeno y sus métodos de uso
EP2790670A1 (en) 2011-12-12 2014-10-22 Leo Laboratories Limited Gel compositions
CN102652730B (zh) 2012-03-29 2014-04-16 武汉华大药业有限公司 软膏基质、苦参绿茶软膏及其制备方法
US8822537B2 (en) * 2012-09-27 2014-09-02 Achelios Therapeutics, Inc. Topical ketoprofen composition
EP2922542A4 (en) 2012-11-21 2016-10-05 Topokine Therapeutics Inc METHODS AND COMPOSITIONS FOR LOCALLY INCREASING BODY FAT
WO2014117999A1 (en) 2013-02-04 2014-08-07 Biocopea Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
AU2014227996B2 (en) * 2013-03-15 2018-08-23 Vapogenix, Inc. Novel analgesic compositions
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
EP3185852A1 (en) 2014-08-27 2017-07-05 AbbVie Inc. Topical formulation
RU2702898C2 (ru) * 2014-09-10 2019-10-14 Гск Консьюмер Хелткер С.А. Композиции диклофенака натрия для местного применения
KR101717699B1 (ko) * 2016-02-11 2017-03-17 아이큐어 주식회사 카타플라스마제용 자외선 경화형 하이드로젤 수지, 하이드로젤 및 이를 포함하는 카타플라스마제
US11666531B2 (en) * 2016-03-31 2023-06-06 Smartech Topical, Inc. Delivery system
CN108210929A (zh) * 2016-12-21 2018-06-29 北京泰德制药股份有限公司 一种含有依托考昔的药物组合物及其制备方法
JP7109092B2 (ja) * 2017-01-31 2022-07-29 帝國製薬株式会社 リドカインおよびジクロフェナクを含む神経障害性疼痛の治療用の医薬用貼付剤
GB201706969D0 (en) * 2017-05-02 2017-06-14 Medherant Ltd Formulation

Also Published As

Publication number Publication date
US20220378729A1 (en) 2022-12-01
CN114615974A (zh) 2022-06-10
EP4054549A1 (en) 2022-09-14
EP4054549A4 (en) 2023-12-06
AU2020379828A1 (en) 2022-04-28
JP7515582B2 (ja) 2024-07-12
JP2022553816A (ja) 2022-12-26
WO2021092238A1 (en) 2021-05-14
US11872199B2 (en) 2024-01-16
CA3155267A1 (en) 2021-05-14
US20230233495A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
MX2022005168A (es) Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso.
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
WO2020084105A3 (en) Compositions for the elimination of senescent cells
EP3778569A4 (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
CL2020002101A1 (es) Formulaciones de liberación sostenida de ácido bempedoico.
AR052104A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa
CL2019003185A1 (es) Formulaciones líquidas estables de protioconazol.
EA202192867A1 (ru) Составы с пролонгированным высвобождением
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina
AR101391A1 (es) Sistema de dos componentes para formulaciones cosméticas
EP3899023A4 (en) METHODS AND COMPOSITIONS FOR REDUCING NON-SPECIFIC AMPLIFICATION IN ISOTHERMAL AMPLIFICATION REACTIONS
AR105894A1 (es) Composición para aplicación tópica que comprende dimetil isosorbida, un poliol, y un antioxidante fenólico o polifenólico
CR20230478A (es) Compuestos de tienopirrol.
EP3677126A4 (en) COMPOSITION OF AGE INHIBITORS, ITS USE, PROCESS OF PREPARATION AND ITS FORMULATION
EP4071155A4 (en) THIAZOLOLACTAM COMPOUND USED AS ERK INHIBITOR AND USE THEREOF
SV2019005811A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
AR109162A1 (es) Formulaciones estables de preservante para madera
EP3805217A4 (en) ERK INHIBITOR AND USES THEREOF
EP3828184A4 (en) PYRAZOLOPYRIMIDI DERIVATIVES AND USE THEREOF AS A PI3K INHIBITOR
DOP2018000211A (es) Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas
AR104671A1 (es) Composiciones de peróxido orgánicas coloreadas
UY37261A (es) Formulación combinada de tres compuestos antivirales
CL2011000768A1 (es) Composicion farmaceutica autoemulsificante antihelmintica veterinaria que comprende 15 a 25% p/v de triclabendazol y un sistema de disolvente no miscible en agua, que comprende 10% a 40% p/v de disolvente de lactona, 10 a 35% p/v de aceite esencial y 30% a 60% p/v de tensioactivo; procedimiento de preparacion; y uso para tratar parasitos.
CO2020006384A2 (es) Combinaciones herbicidas
EP3774708A4 (en) Foxm1 inhibitor compositions and methods of using the same